U2OS E2F7 KO cell line

E2F7 is a transcription factor that participates in various processes such as cell cycle regulation and DNA damage response by mediating transcriptional repression of target genes involved in G1/S regulation as well as in DNA replication and repair.

Contributors

Inventor Institute
Ana Maria Zubiaga ; Iraia Garcia Santisteban University of the Basque Country (EHU)
Cat. #: 156469
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Sarcoma
Research Fields: Cancer;Cell biology
Organism: Human
Tissue: Bone
Model: Knock-Out
Growth properties: Adherent: increased G2/M checkpoint recovery competence and improved viability upon treatment with compounds that affect replication fork progression (cisplatin, mitomycin C, olaparib).
Cancer Types In Detail: Osteosarcoma
Alternate name: U-2 OS
Product description: E2F7 is a transcription factor that participates in various processes such as cell cycle regulation and DNA damage response by mediating transcriptional repression of target genes involved in G1/S regulation as well as in DNA replication and repair. E2F7 behaves as a tumour suppressor by inhibiting DNA repair activity of tumour cells upon chemotherapy treatment. Loss of E2F7 by CRISPR knockout confers increased resistance to chemotherapy in BRCA2-deficient cells. CRISPR edited U2OS cells.
Conditional: No
Production details: E2F7 knockout cells were generated using the CRISPR/Cas9 system. A CRISPR guide RNA (gRNA) targeting the first coding exon of E2F7 was designed using Benchling, and cloned into the BbsI site of pX330 (42230, Addgene). U2OS cells were co-transfected with this plasmid, together with a plasmid containing a gRNA to the zebrafish TIA gene (5 -GGTATGTCGGGAACCTCTCC3 ) and a P2A-puromycin resistance cassette flanked by two TIA target sites. Co-transfection results in excision of the cassette and subs…
Additional notes: CRISPR edited U2OS cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provid…
Parental cell line: U2OS
disease: Cancer
Format: Frozen
Storage conditions: Liquid Nitrogen
Shipping conditions: Dry ice
Growth medium: Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS)
Recommended controls: Parental U2OS cells, puromycin sensitive
Mycoplasma free: Yes
Biosafety level: 1
References:

Mitxelena et al. 2018. Nucleic Acids Res. 46(9):4546-4559. PMID: 29590434.

Related Tools for Cell lines

Cat. # Tool Name
151450 JIM3 Cell Line Key Info View Tool
151558 MEF Trex1 KO Cell Line Key Info View Tool
151576 MEF RAF1 KO Cell Line Key Info View Tool
151626 A375P beta6-puro Cell Line Key Info View Tool
151629 MEF Raf1 FF/FF KI Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.